Biomarker Predicts Appropriate Immunotherapy for Cancer Patients
By LabMedica International staff writers Posted on 14 May 2019 |
Image: A photomicrograph showing tumor-infiltrating lymphocytes in a case of colorectal cancer with evidence of high microsatellite instability (MSI-H) on immunostaining (Photo courtesy of Nephron).
Microsatellite instability (MSI) is a hypermutable phenotype caused by the loss of DNA mismatch repair activity. MSI is detected in about 15% of all colorectal cancers; 3% are of these are associated with Lynch syndrome. MSI is a biomarker for response to immune checkpoint inhibitors (ICPIs).
Programmed death-ligand 1 (PD-1) inhibitors in metastatic colorectal carcinoma (mCRC) with MSI-high (MSI-H) have demonstrated a high disease control rate and favorable progression-free survival (PFS); however, reported response rates to pembrolizumab and nivolumab are variable and often less than 50%, suggesting that additional predictive biomarkers are needed.
A team of scientists working with the City of Hope Comprehensive Cancer Center (Duarte, CA, USA) retrospectively analyzed the data of 22 patients, all of whom had high MSI, a biomarker that indicates they are good candidates to receive immune checkpoint inhibitor treatment. The patients received either pembrolizumab or nivolumab, both of which are approved by the US Food and Drug Administration (FDA, Silver Springs, MD, USA) for metastatic colorectal cancer patients. The scientists looked at tumor characteristics, tumor genomics and outcome data and compared those analyses to a database containing 18,140 metastatic colorectal cancer patients.
Clinico-pathologic data were collected from patients with MSI-H mCRC confirmed by hybrid capture-based next-generation sequencing (NGS) treated with PD-1/L1 inhibitors at five institutes. Tumor mutational burden (TMB) was determined on 0.8-1.1 Mbp of sequenced DNA and reported as mutations/Mb. The team reported that the patients whose tumor cells had a mutation score less than a cut-off point of 37 were less likely to respond to immunotherapy and more likely to have their disease quickly worsen. Those who had a tumor mutation score above the cut-off point of 41 were more likely to respond to pembrolizumab or nivolumab. Notably, the patients who responded to immunotherapy appeared to have durable responses, with the majority experiencing ongoing major shrinkage beyond 1.5 years (the time of study analysis).
Alexa B, Schrock, PhD, an Associate Director, Clinical Development at Foundation Medicine (Cambridge, MA, USA) and the lead author of the study, said, “Comprehensive genomic profiling is critical to assess the underlying genomic drivers of a tumor, as well as important biomarkers that require broad DNA interrogation like tumor mutational burden (TMB) and microsatellite instability (MSI). In this study, we've seen the importance of evaluating both TMB and MSI when making treatment decisions for metastatic colorectal cancer patients.” The study was published on April 30, 2019, in the journal Annals of Oncology.
Related Links:
City of Hope Comprehensive Cancer Center
US Food and Drug Administration
Foundation Medicine
Programmed death-ligand 1 (PD-1) inhibitors in metastatic colorectal carcinoma (mCRC) with MSI-high (MSI-H) have demonstrated a high disease control rate and favorable progression-free survival (PFS); however, reported response rates to pembrolizumab and nivolumab are variable and often less than 50%, suggesting that additional predictive biomarkers are needed.
A team of scientists working with the City of Hope Comprehensive Cancer Center (Duarte, CA, USA) retrospectively analyzed the data of 22 patients, all of whom had high MSI, a biomarker that indicates they are good candidates to receive immune checkpoint inhibitor treatment. The patients received either pembrolizumab or nivolumab, both of which are approved by the US Food and Drug Administration (FDA, Silver Springs, MD, USA) for metastatic colorectal cancer patients. The scientists looked at tumor characteristics, tumor genomics and outcome data and compared those analyses to a database containing 18,140 metastatic colorectal cancer patients.
Clinico-pathologic data were collected from patients with MSI-H mCRC confirmed by hybrid capture-based next-generation sequencing (NGS) treated with PD-1/L1 inhibitors at five institutes. Tumor mutational burden (TMB) was determined on 0.8-1.1 Mbp of sequenced DNA and reported as mutations/Mb. The team reported that the patients whose tumor cells had a mutation score less than a cut-off point of 37 were less likely to respond to immunotherapy and more likely to have their disease quickly worsen. Those who had a tumor mutation score above the cut-off point of 41 were more likely to respond to pembrolizumab or nivolumab. Notably, the patients who responded to immunotherapy appeared to have durable responses, with the majority experiencing ongoing major shrinkage beyond 1.5 years (the time of study analysis).
Alexa B, Schrock, PhD, an Associate Director, Clinical Development at Foundation Medicine (Cambridge, MA, USA) and the lead author of the study, said, “Comprehensive genomic profiling is critical to assess the underlying genomic drivers of a tumor, as well as important biomarkers that require broad DNA interrogation like tumor mutational burden (TMB) and microsatellite instability (MSI). In this study, we've seen the importance of evaluating both TMB and MSI when making treatment decisions for metastatic colorectal cancer patients.” The study was published on April 30, 2019, in the journal Annals of Oncology.
Related Links:
City of Hope Comprehensive Cancer Center
US Food and Drug Administration
Foundation Medicine
Latest Pathology News
- Robotic Blood Drawing Device to Revolutionize Sample Collection for Diagnostic Testing
- Use of DICOM Images for Pathology Diagnostics Marks Significant Step towards Standardization
- First of Its Kind Universal Tool to Revolutionize Sample Collection for Diagnostic Tests
- AI-Powered Digital Imaging System to Revolutionize Cancer Diagnosis
- New Mycobacterium Tuberculosis Panel to Support Real-Time Surveillance and Combat Antimicrobial Resistance
- New Method Offers Sustainable Approach to Universal Metabolic Cancer Diagnosis
- Spatial Tissue Analysis Identifies Patterns Associated With Ovarian Cancer Relapse
- Unique Hand-Warming Technology Supports High-Quality Fingertip Blood Sample Collection
- Image-Based AI Shows Promise for Parasite Detection in Digitized Stool Samples
- Deep Learning Powered AI Algorithms Improve Skin Cancer Diagnostic Accuracy
- Microfluidic Device for Cancer Detection Precisely Separates Tumor Entities
- Virtual Skin Biopsy Determines Presence of Cancerous Cells
- AI Detects Viable Tumor Cells for Accurate Bone Cancer Prognoses Post Chemotherapy
- First Ever Technique Identifies Single Cancer Cells in Blood for Targeted Treatments
- Innovative Blood Collection Device Overcomes Common Obstacles Related to Phlebotomy
- Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes